At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-arm Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients With Advanced Cholangiocarcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Olaparib for Cholangiocarcinoma. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The investigators propose an open label, one-arm study to assess the safety and efficacy of olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or cannot tolerate gemcitabine-based therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartApr 2020
Primary CompletionJul 2023
Study CompletionDec 2024
TodayJul 2026
First PostedMar 12, 2020
Enrollment StartApr 1, 2020
Primary CompletionJul 16, 2023
Study CompletionDec 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.3 years ago
Interventions
Pembrolizumabdrug
200 mg given intravenously.
Olaparibdrug
300 mg given orally.